KNSAKiniksa Pharmaceuticals, Ltd.

$3B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$123M+46.9% YoY

Gross Profit

$56M46.0% margin

Operating Income

-$19M-15.7% margin

Net Income

-$9M-7.3% margin

EPS (Diluted)

$-0.12

QoQ Revenue Growth

+9.2%

Cash Flow

Operating Cash Flow

$19M

Free Cash Flow

$19M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$581M

Total Liabilities

$142M

Stockholders' Equity

$438M

Cash & Equivalents

$184M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$123M	$83M	+46.9%
Gross Profit	$56M	$57M	-0.5%
Operating Income	-$19M	$81,000	-23925.9%
Net Income	-$9M	$25M	-135.2%

Revenue Segments

Product

$201M100%

KNSA Q4 2024 Earnings — Kiniksa Pharmaceuticals, Ltd. Revenue & Financial Results | Market Cap Arena